ArticleOncotarget2017

Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.

Patrick M Reeves et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.